BiLi

Quick links to important sections

BiLi

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of BiLi

Quick Facts

Property Description
Active ingredient Granisetron hydrochloride
Form Oral tablet, injectable solution, transdermal patch
Pharmacological class Selective 5-HT3 receptor antagonist
Common use Prevention of sickness and vomiting
Origin Synthetic (Chemically synthesized)

What Type of Medicine is BiLi?

The drug BiLi is a proprietary pharmaceutical product whose primary component is granisetron, supplied as granisetron hydrochloride. It is formally classified as a selective 5-HT3 receptor antagonist, belonging to the larger class of antiemetic medicines designed to prevent and suppress nausea and vomiting. This classification is clinically recognized for its targeted efficacy compared to older, less specific agents. Granisetron is utilized for its highly focused activity, which targets a specific chemical sensor in the body. Granisetron acts as an agent for blocking the receptors that transmit signals for sickness, helping to maintain patient comfort.

Composition, Origin, and Available Forms

The core ingredient, granisetron, is a synthetic compound, a small molecule created entirely through chemical synthesis. As a single-component product, its formulation ensures consistency across its multiple available physical presentations. It is manufactured in distinct pharmaceutical preparations, including the standard oral tablet, the injectable solution for intravenous administration, and the specialized, long-acting transdermal patch. The diversity of these forms provides flexibility in its administration. This range of options, particularly the transdermal delivery system, offers a key differentiating factor, enabling use for patients unable to tolerate oral intake or requiring sustained delivery.

The General Purpose of Granisetron

The fundamental general benefit of granisetron stems from its role as a potent antagonist against the serotonin signaling pathway. Serotonin, a natural substance, can act as a key messenger that stimulates the nausea and vomiting centers. Granisetron counteracts this by effectively blocking the 5-HT3 receptors found both in the digestive tract and in the brainstem. This high-level inhibition prevents the transmission of distress signals, providing a targeted and effective means of stabilizing the patient and reducing the incidence of sickness in appropriate clinical scenarios.

Regulatory References

  1. Granisetron: MedlinePlus Drug Information

What side effects are possible with BiLi?

Possible Side Effects and Safety Information

The safety profile of BiLi, whose active ingredient is granisetron, is based on official classifications and documented adverse reactions from regulatory sources. The most frequently reported adverse reactions are generally transient.

Adverse Reaction Scope

Classification Examples of Reactions
Very Common Headache, Constipation.
Common Insomnia, Elevated hepatic transaminases (AST/ALT), Diarrhea, Asthenia (Weakness).
Uncommon Hypersensitivity reactions, QT prolongation, Extrapyramidal reactions.

These effects are grouped by body system, including Nervous System Disorders (e.g., headache), Gastrointestinal Disorders (e.g., constipation), and Hepatobiliary Disorders (elevated enzymes).

Serious Reactions and Safety Constraints

Official labeling documents specific serious reactions. These include QT interval prolongation (an ECG change) and the potential for Serotonin Syndrome when used concomitantly with other serotonergic medications. Severe hypersensitivity reactions (e.g., anaphylaxis) are also documented.

Safety constraints noted in regulatory documents include exercising caution in patients with pre-existing cardiac conduction issues or electrolyte abnormalities. Furthermore, granisetron may mask underlying bowel conditions, such as ileus or gastric distention. Regarding special populations, safety and effectiveness have not been established in children under two years of age, and avoidance is generally advised during pregnancy and lactation due to limited data.

The regulatory frequency framework distinguishes between common, often transient effects and specific uncommon but clinically significant events, which structures the official understanding of the medicine’s risk profile.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents for BiLi (granisetron) describe the presentation of overdose, necessary immediate actions, and required medical management. All overdose information is based on label-documented risks and mandated response procedures.

Overdose has been reported in clinical scenarios, with the most commonly documented clinical manifestation being a mild headache following high-dose intravenous administration. However, the primary focus of emergency guidance is on potential serious systemic risks.

When to Seek Immediate Medical Attention

It is officially mandated to seek immediate medical attention and contact emergency services (e.g., call 911) if specific severe symptoms develop. These serious manifestations are consistent with Serotonin Syndrome and include:

  • Changes in mental status (such as confusion or agitation).
  • Neuromuscular symptoms (including overactive reflexes or muscle twitching).
  • Signs of autonomic instability (like a fast heartbeat or excessive sweating).

If these symptoms occur, regulatory guidance requires the discontinuation of granisetron.

Overdose Management

The official labeling explicitly states that no specific antidote is known for BiLi overdose. Therefore, the management strategy defined in regulatory documentation is entirely focused on providing symptomatic and supportive treatment. Furthermore, due to the drug’s potential effect on bowel motility, patients with risk factors for obstruction may require monitoring for decreased bowel activity.

Therapeutic Uses of BiLi

Main Uses and Therapeutic Benefits of BiLi (Granisetron)

BiLi is used in specific clinical settings and is applied in addressing distressing symptoms related to intense nausea and vomiting (emesis), symptoms related to heightened physiological activity. Granisetron hydrochloride is approved to prevent nausea and vomiting caused by chemotherapy and radiation therapy. The medication is primarily applied in conditions characterized by periods of heightened symptoms, which include: symptoms associated with highly emetogenic chemotherapy, manifestations linked to radiation therapy, and Post-Operative Nausea and Vomiting (PONV) in surgical recovery.

The Role in Symptom Management

A key therapeutic benefit is that BiLi helps address symptom clusters that may become intense or disruptive, helping patients cope more steadily during difficult episodes. This supportive symptomatic assistance contributes to improved comfort during periods of heightened symptoms. May assist with supporting adherence to treatment plans.

“Symptom management is relevant in contexts involving heightened systemic burden; BiLi supports general well-being during symptomatic phases.”

Quick Fact: Relief for Acute and Delayed Sickness

Category Typical Contexts Benefit Provided
Symptom Domain Chemotherapy (CINV), Radiation (RINV), Surgery (PONV) May assist with supporting adherence to treatment plans.
Symptom Focus Nausea, Vomiting, Retching Helps maintain a sense of stability.

Regulatory References

  1. NCI overview of Granisetron Hydrochloride

Eligibility and Restrictions for Use

Who Can and Cannot Use BiLi? (Granisetron)

Official regulatory documents define the strict eligibility criteria for using BiLi (granisetron) based on patient population, age, and pre-existing conditions.


Populations Prohibited or Restricted from Use

Classification Eligibility Rule (Official Labeling Status)
Absolute Contraindication Patients with known hypersensitivity (allergy) to granisetron or any component of the formulation. Concomitant use with apomorphine is also prohibited.
Use Not Established Pediatric patients younger than 2 years of age have not had safety and effectiveness established. Efficacy is also not established for Post-Operative Nausea and Vomiting (PONV) in the entire pediatric population ( ages < 18).
Use Restricted (Caution) Caution is required in patients with a history of cardiac conduction disorders (e.g., arrhythmias) due to the potential for QT prolongation. Caution is also required in patients with signs of sub-acute intestinal obstruction or chronic constipation due to potential reduction in bowel motility.

Established Eligibility

Population Group Regulatory Status
Adults and Older Adults Use is established and generally requires no special precautions.
Pediatric Patients Established for chemotherapy- and radiation-induced nausea and vomiting (CINV/RINV) in children aged 2 years and older.
Organ Impairment No specific dose adjustment is necessary for patients with renal impairment or hepatic impairment (liver function).
Pregnancy/Lactation Use is not recommended during pregnancy unless clearly necessary, and breastfeeding should be discontinued during therapy.

This structure reflects how regulatory bodies officially classify patient groups into allowed, restricted, or prohibited categories for granisetron use.

What should I know about interactions with other medicines?

BiLi Interactions with Other Medicines and Products (Granisetron Hydrochloride)

This section summarizes the officially documented interaction patterns for BiLi, strictly according to government regulatory information.


Pharmacodynamic Interactions

Interactions involving a combined effect on the central nervous system or heart function are reported. Regulatory documents note a risk when BiLi is combined with other serotonergic medicinal products, including SSRIs, SNRIs, certain opioids, and triptans, which has been associated with reports of serotonin syndrome.

Caution is advised with co-administration alongside medicines known to prolong the QT interval and/or those classified as arrhythmogenic.

Contraindicated Combination

Combination Regulatory Status
Apomorphine Officially classified as a contraindicated combination due to the risk of increased QT prolongation.

Pharmacokinetic and Exposure Interactions

BiLi is metabolized by hepatic cytochrome P-450 enzymes (CYP1A1 and CYP3A4). The official labeling indicates that inducers or inhibitors of these enzymes may potentially alter the clearance and half-life of granisetron.

  • Phenobarbital, an enzyme inducer, has been documented to increase the total plasma clearance of BiLi.
  • No specific interactions with food, alcohol, or herbal products are explicitly detailed in the official regulatory prescribing information.

Population-Specific Notes

A degree of caution must be exercised in patients with hepatic impairment, based on the drug's metabolic profile, although no increased incidence of adverse reactions has been observed in this population.

Mechanism of Action

BiLi (bilastine) is a compound that functions as a highly selective inverse agonist at the histamine H1 receptor. Its primary biological targets are peripheral H1 receptors expressed on various cells, including endothelial and smooth muscle cells. The compound exhibits negligible affinity for other receptors, such as muscarinic, serotonergic, and adrenergic subtypes, contributing to its selective action. By binding to and stabilizing the H1 receptor in an inactive conformation, BiLi shifts the receptor equilibrium away from the active state, thereby competitively antagonizing the effects of endogenous histamine. This molecular interaction interrupts the intracellular signaling pathway mediated by the H1 receptor, which involves Gq-protein coupling leading to the activation of phospholipase C and subsequent release of calcium from internal stores. The resulting downstream cascade includes the modulation of microvascular permeability and inhibition of histamine-induced smooth muscle contraction, leading to systemic physiological consequences that involve the reduction of localized tissue responses mediated by mast cell degranulation and histamine release.

Dosage and Administration Information

Official Administration Guidelines for BiLi (Granisetron)

The administration of Granisetron is highly defined by the official instructions to ensure proper use across its diverse formulations. The medicine is supplied in several forms, including oral tablets and solution, intravenous (IV) injection for immediate use, a transdermal patch, and a subcutaneous (SC) injection for extended-release delivery. These options determine the appropriate route of administration, which may be oral, intravenous, topical, or subcutaneous.

Dosing and Timing

Administration is strictly scheduled in relation to the event causing sickness, rather than for general, continuous use. For preventing chemotherapy-induced sickness (CINV), the medicine is typically administered prior to the start of chemotherapy, often 30 minutes to 1 hour before the procedure. Oral dosing for CINV prevention is typically 1 mg taken twice daily, or a single 2 mg dose. The single IV dose for adults in this setting is usually 10 mcg/kg. The maximum total dose administered over a 24-hour period should not exceed 9 mg via oral or IV routes.

Administration Route Standard Adult Dose Principle Timing Constraint
Oral (Tablet/Solution) 1 mg twice daily or single 2 mg dose. Administer 1 hour before chemotherapy.
Intravenous (IV) 10 mcg/kg or 1 mg to 3 mg fixed dose. Administer 30 minutes before the procedure.
Transdermal Patch Single patch releasing 3.1 mg/24 hours. Apply 24 to 48 hours before chemotherapy.

Procedural Use and Adjustments

Granisetron may be taken with or without food when using the oral form. The transdermal patch must be applied to the intact skin of the upper arm or abdomen, and worn for up to 7 days but must be removed a maximum of 24 hours after the last administration of chemotherapy. For pediatric patients (aged 2 to 16 years), the IV dose is based on weight (10 mcg/kg). No routine dosage adjustment is required for older adults or patients with renal or hepatic impairment. The administration protocol ensures the drug is present in the system during the period of maximum risk of sickness.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Trial Analysis

Studies investigated the drug's activity.

  • One study reported that researchers observed a reduction in symptoms over the study period in a small cohort of participants with a specific, mild condition.
  • Researchers evaluated the effect on pain and relief of discomfort.
  • The primary endpoint of the trial focused on measuring the change in a specific biomarker over the study duration.

Safety and Tolerability Profile

Clinical trials examined the active ingredient's effect on the condition. Clinical studies reported that the most frequent adverse events observed were mild headaches and temporary gastrointestinal discomfort.

  • Research did not specifically study the compound's effect in most populations. Studies excluded participants with kidney issues.
  • Studies did not provide data on the effects of discontinuing use.
  • Research did not compare the treatment to other established methods.

Frequently Asked Questions (FAQ)

Common questions about BiLi (FAQ)


Q: How quickly does BiLi typically start to work?

Official administration instructions detail that the medicine is administered for prevention, typically between 30 minutes to one hour before the start of a procedure, such as chemotherapy. This timing reflects the period when the drug is intended to provide its preventative action.


Q: What should I do if I think BiLi isn't working for me?

If continuous severe sickness or vomiting occurs even after receiving the medicine according to the prescribed protocol, official patient guidance recommends contacting a healthcare provider. This allows for a reassessment based on the treatment protocol.


Q: Why does the packaging for BiLi include a warning about alcohol?

The core regulatory prescribing information does not specifically detail a chemical interaction between the drug and alcohol. However, patient guidance is generally offered because combining the drug with alcohol could potentially lead to an increase in certain central nervous system (CNS) effects, such as dizziness.


Q: Can BiLi be taken with vitamins or supplements?

Official regulatory documents prioritize detailing interactions with prescription drugs like serotonergic products and those that affect the heart’s electrical activity. Information regarding non-prescription vitamins or general supplements is not explicitly outlined in the regulatory prescribing data.


Q: What happens if I accidentally take more BiLi than directed?

In the event that the prescribed amount is exceeded, official patient guidance notes the importance of contacting a doctor, hospital emergency department, or poison control center for direction regarding the overdose protocol.


Q: Why is it important to finish the full course of BiLi?

The drug is prescribed for a defined period, whether it involves a full oral course or applying the transdermal patch for up to seven days. This administration strategy helps maintain the presence of the active medication in the system throughout the designated period of potential risk for sickness and vomiting.


Q: Is BiLi a new medicine or has it been around for a long time?

The active ingredient in BiLi, granisetron, has been approved and utilized in many countries since the early 1990s. This indicates a long history of use for the core component, although some specific delivery methods have received regulatory approval more recently.


Q: If I miss a dose of BiLi, what should I do?

Official patient instructions generally describe taking the tablet as soon as it is remembered if a dose is missed. If there is confusion or vomiting occurs, professional guidance involves contacting a doctor for advice, rather than attempting to double a dose.


Q: Why do some people say BiLi causes weight gain?

Weight gain is not listed as a Very Common, Common, or Uncommon adverse reaction in the official regulatory documents describing the medicine's safety profile. Conversely, official documents have listed 'anorexia,' or loss of appetite, as a common side effect in some contexts.


Q: Are there generic versions of BiLi available?

The active ingredient, granisetron, is widely available in generic formulations, including oral tablets and injectable solutions. However, some specialized or extended-release forms, such as the transdermal patch, may only be available as the branded product.


Q: Can BiLi cause stomach upset or nausea?

Official regulatory safety information notes that certain gastrointestinal effects have been reported, including constipation, diarrhea, and abdominal pain. Although the medicine is intended to prevent sickness, regulatory documents have also listed nausea and vomiting as reported adverse events in some contexts.


Q: What should I do if I get a rash while taking BiLi?

Official warnings state that uncommon adverse reactions can include skin rashes and other hypersensitivity events. If signs of hypersensitivity, such as a rash, hives, or swelling, are experienced, official patient guidance highlights the importance of seeking prompt medical attention.


Q: Can BiLi be crushed or chewed?

The oral tablets are typically film-coated formulations. Film-coated medications are not typically designed to be altered by crushing or chewing. This ensures the integrity and intended absorption characteristics of the medicine are maintained.


Q: Are there lifestyle changes that can help BiLi work better?

Official patient information focuses on mitigating common side effects, such as constipation or diarrhea, by ensuring adequate fluid intake. It may also advise eating certain low-fiber foods, if instructed, to help manage gastrointestinal comfort while taking the medicine.


Q: Does BiLi require regular blood tests?

While the drug is known to cause a transient (temporary) elevation of hepatic transaminases, which are liver enzymes, the official prescribing information does not typically mandate routine blood tests for monitoring liver or kidney function in otherwise healthy patients.


Q: What does 'clinical trial' mean when talking about BiLi?

A clinical trial is defined as a research study conducted with human volunteers that tests a medical intervention, such as a new drug like BiLi. These studies are the principal method researchers use to determine if a treatment is considered safe and effective for a specific health condition.


Q: Can BiLi be taken with food if it causes stomach irritation?

The official administration guidelines for the oral tablet formulation state that the medicine can be taken either with or without food. This provides flexibility for administration, especially if taking it with a meal helps reduce any mild stomach irritation.

How should BiLi be stored and disposed of?

How to Store and Dispose of BiLi (Granisetron)

The storage and disposal requirements for BiLi are defined by official regulatory documentation to ensure product stability and safety. Requirements differ based on the specific formulation.


Official Storage Requirements

Formulation Required Storage Condition Handling/Protection Rule
Oral Tablets Controlled Room Temperature (20 C to 25 C) Keep tightly closed in the container; protect from light and moisture.
Injectable Solution Varies by formulation; protect ampoules in the outer carton. Diluted solutions are stable for up to 24 hours at room temperature.
Transdermal Patch Store in the original package until ready to use. Application site must be covered for 10 days post-removal to avoid sunlight.

Child Safety and Disposal

All forms of the medication must be stored out of the sight and reach of children, and safety caps must always be locked. For disposal, the preferred method is a drug take-back program. If unavailable, the medication should be mixed with an undesirable substance, placed in a sealed container, and discarded in the household trash. Used transdermal patches must be folded with the sticky sides together prior to disposal. Regulatory guidance advises against flushing this medication down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of BiLi found in:

A-Z Index: